Table of Contents:

• Prevalence of Cardiovascular Disease, Diabetes, and the Metabolic Syndrome
• Overview of Atherogenic Dyslipidemia and Cardiometabolic Risk.
• Residual CVD Risk Remains a Major Obstacle After Statin Therapy
• Role of Atherogenic Dyslipidemia in Residual CVD Risk
• National Guidelines: Risk Classifi cation of Atherogenic Lipoprotein Abnormalities
• National Guidelines: Therapeutic Treatment Options for Atherogenic Lipoprotein Abnormalities
• Failure of High-Risk Patients to Achieve Recommended Treatment Targets Combination Lipid-Modifying Therapy: Clinical Trial Evidence
• Ongoing Combination Lipid-Modifying Therapy Outcomes Trials
• Summary
• References

Clinicians involved in the management of patients with Atherogenic Dyslipidemia.

Written By:
Gregory Pokrywka, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Reviewed By:
Tufts University School of Medicine

Edited By:
Jean Baker, MS, RD